Abstract
Safe and efficient prophylactic and therapeutic vaccines are lacking for a number of infectious diseases and immunologically related disorders. Novel adjuvants, able to enhance and modify immune responses, thus have the potential to improve both prophylactic and therapeutic vaccines. In the search for new types of adjuvants the carbohydrate polymer chitosan has gained increasing interest. Chitosan derives from the natural product chitin and chemically consists of N-acetyl-glucosamine and glucosamine. Attractive characteristics of chitosan as an adjuvant candidate include its natural origin, full biodegradability, non-toxicity and low cost of goods. Chitosan has the ability to stimulate innate immunity but the mechanism of action is not fully understood. The adjuvant effect may also be mediated by improved antigen presentation to immune cells and by enhancing the antigen uptake. Because of its cationic character chitosan adheres to mucosal surfaces. Various chemical derivatives and particulate variants of chitosan have been explored for mucosal administration of vaccines. Available data from clinical trials support chitosan as being a useful adjuvant- and delivery system for intranasal vaccines. In order to develop chitosan based adjuvants for different vaccine applications and administration routes it is crucial to provide high-quality medical grade chitosan. In this chapter we present published data on chitosan as an adjuvant and specifically focus on a recently developed chitosan based adjuvant, ViscoGel.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Nossal, G.J.: Vaccines of the future. Vaccine 29 Suppl 4, D111–D115 (2011). doi:10.1016/j.vaccine.2011.06.089. S0264-410X(11)00983-2 [pii]
Leroux-Roels, G.: Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine 28 Suppl 3, C25–C36 (2010). doi:10.1016/j.vaccine.2010.07.021. S0264-410X(10)01004-2 [pii]
McElhaney, J.E.: Prevention of infectious diseases in older adults through immunization: the challenge of the senescent immune response. Expert Rev. Vaccines 8, 593–606 (2009). doi:10.1586/erv.09.12
Schubert, C.: New vaccine tailored to the weakened elderly immune system. Nat. Med. 16, 137 (2010). doi:10.1038/nm0210-137a. nm0210-137a [pii]
Brewer, J.M., et al.: Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. J. Immunol. 163, 6448–6454 (1999). ji_v163n12p6448 [pii]
Mbow, M.L., De Gregorio, E., Valiante, N.M., Rappuoli, R.: New adjuvants for human vaccines. Curr. Opin. Immunol. 22, 411–416 (2010). doi:10.1016/j.coi.2010.04.004. S0952-7915(10)00068-3 [pii]
Schijns, V.E., Lavelle, E.C.: Trends in vaccine adjuvants. Expert Rev. Vaccines 10, 539–550 (2011). doi:10.1586/erv.11.21
Jabbal-Gill, I., Fisher, A.N., Rappuoli, R., Davis, S.S., Illum, L.: Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. Vaccine 16, 2039–2046 (1998). S0264410X98000772 [pii]
Zaharoff, D.A., Rogers, C.J., Hance, K.W., Schlom, J., Greiner, J.W.: Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine 25, 2085–2094 (2007). doi:10.1016/j.vaccine.2006.11.034. S0264-410X(06)01225-4 [pii]
Bonferoni, M.C., Sandri, G., Rossi, S., Ferrari, F., Caramella, C.: Chitosan and its salts for mucosal and transmucosal delivery. Expert Opin. Drug Deliv. 6, 923–939 (2009). doi:10.1517/17425240903114142
Sorlier, P., Denuziere, A., Viton, C., Domard, A.: Relation between the degree of acetylation and the electrostatic properties of chitin and chitosan. Biomacromolecules 2, 765–772 (2001)
Kumar, M.N., Muzzarelli, R.A., Muzzarelli, C., Sashiwa, H., Domb, A.J.: Chitosan chemistry and pharmaceutical perspectives. Chem. Rev. 104, 6017–6084 (2004). doi:10.1021/cr030441b
Illum, L., Farraj, N.F., Davis, S.S.: Chitosan as a novel nasal delivery system for peptide drugs. Pharm. Res. 11, 1186–1189 (1994)
Alves, N.M., Mano, J.F.: Chitosan derivatives obtained by chemical modifications for biomedical and environmental applications. Int. J. Biol. Macromol. 43, 401–414 (2008). doi:10.1016/j.ijbiomac.2008.09.007. S0141-8130(08)00208-0 [pii]
Arca, H.C., Gunbeyaz, M., Senel, S.: Chitosan-based systems for the delivery of vaccine antigens. Expert Rev. Vaccines 8, 937 (2009). doi:10.1586/erv.09.47
Jabbal-Gill, I., Watts, P., Smith, A.: Chitosan-based delivery systems for mucosal vaccines. Expert Opin. Drug Deliv. 9, 1051–1067 (2012). doi:10.1517/17425247.2012.697455
Luppi, B., Bigucci, F., Cerchiara, T., Zecchi, V.: Chitosan-based hydrogels for nasal drug delivery: from inserts to nanoparticles. Expert Opin. Drug Deliv. 7, 811–828 (2010). doi:10.1517/17425247.2010.495981
Gronlund, H., et al.: Carbohydrate-based particles: a new adjuvant for allergen-specific immunotherapy. Immunology 107, 523–529 (2002). 1535 [pii]
Kamath, A.T., et al.: Synchronization of dendritic cell activation and antigen exposure is required for the induction of Th1/Th17 responses. J. Immunol. 188, 4828–4837 (2012). doi:10.4049/jimmunol.1103183. jimmunol.1103183 [pii]
Kovacsovics-Bankowski, M., Clark, K., Benacerraf, B., Rock, K.L.: Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc. Natl. Acad. Sci. U.S.A. 90, 4942–4946 (1993)
Vila, A., Sanchez, A., Tobio, M., Calvo, P., Alonso, M.J.: Design of biodegradable particles for protein delivery. J. Control. Release 78, 15–24 (2002). S0168365901004862 [pii]
Vila, A., et al.: Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur. J. Pharm. Biopharm. 57, 123–131 (2004). S0939641103001620 [pii]
Amidi, M., et al.: Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system. J. Control. Release 111, 107–116 (2006). doi:10.1016/j.jconrel.2005.11.014. S0168-3659(05)00652-8 [pii]
Saint-Lu, N., et al.: Targeting the allergen to oral dendritic cells with mucoadhesive chitosan particles enhances tolerance induction. Allergy 64, 1003–1013 (2009). doi:10.1111/j.1398-9995.2009.01945.x. ALL1945 [pii]
Porporatto, C., Bianco, I.D., Correa, S.G.: Local and systemic activity of the polysaccharide chitosan at lymphoid tissues after oral administration. J. Leukoc. Biol. 78, 62–69 (2005). doi:10.1189/jlb.0904541. jlb.0904541 [pii]
Neimert-Andersson, T., et al.: Improved immune responses in mice using the novel chitosan adjuvant ViscoGel, with a haemophilus influenzae type b glycoconjugate vaccine. Vaccine 29, 8965–8973 (2011). doi:10.1016/j.vaccine.2011.09.041. S0264-410X(11)01447-2 [pii]
Ghendon, Y., et al.: Evaluation of properties of chitosan as an adjuvant for inactivated influenza vaccines administered parenterally. J. Med. Virol. 81, 494–506 (2009). doi:10.1002/jmv.21415
Lee, C.G., Da Silva, C.A., Lee, J.Y., Hartl, D., Elias, J.A.: Chitin regulation of immune responses: an old molecule with new roles. Curr. Opin. Immunol. 20, 684–689 (2008). doi:10.1016/j.coi.2008.10.002. S0952-7915(08)00185-4 [pii]
Shibata, Y., Metzger, W.J., Myrvik, Q.N.: Chitin particle-induced cell-mediated immunity is inhibited by soluble mannan: mannose receptor-mediated phagocytosis initiates IL-12 production. J. Immunol. 159, 2462–2467 (1997)
Da Silva, C.A., Hartl, D., Liu, W., Lee, C.G., Elias, J.A.: TLR-2 and IL-17A in chitin-induced macrophage activation and acute inflammation. J. Immunol. 181, 4279–4286 (2008). 181/6/4279 [pii]
Da Silva, C.A., Pochard, P., Lee, C.G., Elias, J.A.: Chitin particles are multifaceted immune adjuvants. Am. J. Respir. Crit. Care Med. 182, 1482–1491 (2010). doi:10.1164/rccm.200912-1877OC. 200912-1877OC [pii]
Mora-Montes, H.M., et al.: Recognition and blocking of innate immunity cells by Candida albicans chitin. Infect. Immun. 79, 1961–1970 (2011). doi:10.1128/IAI.01282-10. IAI.01282-10 [pii]
Peluso, G., et al.: Chitosan-mediated stimulation of macrophage function. Biomaterials 15, 1215–1220 (1994)
Li, H., Willingham, S.B., Ting, J.P., Re, F.: Cutting edge: inflammasome activation by alum and alum’s adjuvant effect are mediated by NLRP3. J. Immunol. 181, 17–21 (2008). 181/1/17 [pii]
Mori, A., et al.: The vaccine adjuvant alum inhibits IL-12 by promoting PI3 kinase signaling while chitosan does not inhibit IL-12 and enhances Th1 and Th17 responses. Eur. J. Immunol. (2012). doi:10.1002/eji.201242372
Hallander, H.O., Lepp, T., Ljungman, M., Netterlid, E., Andersson, M.: Do we need a booster of Hib vaccine after primary vaccination? A study on anti-Hib seroprevalence in Sweden 5 and 15 years after the introduction of universal Hib vaccination related to notifications of invasive disease. APMIS 118, 878–887 (2010). doi:10.1111/j.1600-0463.2010.02674.x
Muzzarelli, R.A.: Chitins and chitosans as immunoadjuvants and non-allergenic drug carriers. Mar. Drugs 8, 292–312 (2010). doi:10.3390/md8020292
Mills, K.H., et al.: Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a. Infect. Immun. 71, 726–732 (2003)
McNeela, E.A., et al.: Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. Vaccine 22, 909–914 (2004). doi:10.1016/j.vaccine.2003.09.012. S0264410X03006728 [pii]
Read, R.C., et al.: Effective nasal influenza vaccine delivery using chitosan. Vaccine 23, 4367–4374 (2005). doi:10.1016/j.vaccine.2005.04.021. S0264-410X(05)00463-9 [pii]
Huo, Z., et al.: Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixed with chitosan. Infect. Immun. 73, 8256–8265 (2005). doi:10.1128/IAI.73.12.8256-8265.2005. 73/12/8256 [pii]
El-Kamary, S.S., et al.: Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J. Infect. Dis. 202, 1649–1658 (2010). doi:10.1086/657087
Atmar, R.L., et al.: Norovirus vaccine against experimental human Norwalk Virus illness. N. Engl. J. Med. 365, 2178–2187 (2011). doi:10.1056/NEJMoa1101245
Mucovac2. http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=11679 (2012)
Li, X., et al.: Preliminary safety and efficacy results of laser immunotherapy for the treatment of metastatic breast cancer patients. Photochem. Photobiol. Sci. 10, 817–821 (2011). doi:10.1039/c0pp00306a
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Gafvelin, G., Grönlund, H. (2014). Chitosan-Based Adjuvants. In: Giese, M. (eds) Molecular Vaccines. Springer, Cham. https://doi.org/10.1007/978-3-319-00978-0_13
Download citation
DOI: https://doi.org/10.1007/978-3-319-00978-0_13
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-00977-3
Online ISBN: 978-3-319-00978-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)